American Heart Journal
Volume 152, Issue 1 , Pages 19-26 , July 2006

Heparin-induced thrombocytopenia and cardiovascular diseases

Received 25 June 2005 ,Accepted 13 October 2005.

References 

  1. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;11:2671–2683
  2. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995;332:1374–1376
  3. Spencer FA. Heparin-induced thrombocytopenia: patient profiles and clinical manifestations. J Thromb Thrombolysis. 2000;10:S21–S25
  4. Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000;10:S13–S20
  5. Ohman EM, Granger CB, Rice L, et al. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) registry steering committee. J Thromb Thrombolysis. 2005;9:11–19
  6. Oliveira GB, Anstrom KJ, Honeycutt EF, et al. Days on intravenous heparin predicts thrombocytopenia and drop in platelet count on heparin predicts mortality: findings from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. [abstract] Circulation. 2004;110(Suppl):2604
  7. Warkentin TE, Levine MN, Hirsh J, et al. Heparin induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335
  8. Warkentin TE, Sheppard H, Horsewood P, et al. Impact of the patient population on the risk for heparin induced thrombocytopenia. Blood. 2000;96:1703–1708
  9. Warkentin TE. Heparin induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1990;50:129–147
  10. Kappers-Klune MC, Boon DM, Hop WC, et al. Heparin induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol. 1997;96:442–446
  11. Warkentin TE, Greinacher A. Heparin induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76:638–648
  12. Hourigan LA, Walters DL, Keck SA, et al. Heparin induced thrombocytopenia: a common complication in cardiac transplant recipients. J Heart Lung Transplant. 2002;21:1283–1289
  13. Warkentin TG, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet derived micro-particles with procoagulant activity; an explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood. 1994;84:3691–3699
  14. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia; towards consensus. Thromb Haemost. 1998;79:1–7
  15. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin 8. Blood. 20001;98:1252–1254
  16. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial cell injury in heparin-induced thrombocytopenia. N Engl J Med. 1987;316:581–589
  17. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286–1292
  18. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37–42
  19. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502–506
  20. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–507
  21. Liu JC, Lewis BE, Steen LH, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol. 2002;89:979–981
  22. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804–812
  23. Warkentin TE, Roberts RS, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome. A nested cohort study. Chest. 2005;127:1857–1861
  24. Kelton JG, Hursting MJ, Lewis BE. The predictors of clinical outcome in patients with heparin induced thrombocytopenia. [Abstract] Blood. 2001;98(pt 1):36a
  25. Bartholomew JR, Begelman SM, Almahameed A. Heparin-induced thrombocytopenia. Principles for early recognition and management. Cleve Clin J Med. 2005;72(Suppl):S31–S36
  26. Warkentin TE, Greiacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:311S–337S
  27. Hursting MJ, Alford KL, Becker JC, et al. Argatroban: a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503–516
  28. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1833–1843
  29. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849–1856
  30. Markwardt F, Nowak G, Sturzebecher J, et al. Clinico-pharmacological studies with recombinant hirudin. Thromb Res. 1988;52:393–400
  31. Greiacher A, Janssens U, Berg G, et al. Lepirudin for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999;100:587–593
  32. Greiacher A, Volpel H, Janssens U, et al. Lepirudin provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73–80
  33. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. J Clin Invest. 1990;29:7095–7101
  34. Lincoff MA, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:859–863
  35. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study. J Invasive Cardiol. 2003;15:611–6167
  36. Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of factor Xa. Best Pract Res Clin Hematol. 2004;17:89–104
  37. Yusuf S, Mehta SR. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-5)/Michelangelo. In: Presented in the European Society of Cardiology Meeting, 2005, Stockholm, Sweden. 2005;
  38. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving anti-thrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;August 18, [Epub ahead of print]
  39. Chong BH, Gallus AS, Cade JF, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001;86:1170–1175
  40. Matsuo T, Tomaru T, Kario K, et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res. 2005;115:475–481
  41. Crespo EM, Becker RC, Berger PB, et al. Incidence and evaluation of heparin-induced thrombocytopenia among patients with prolonged heparin and among thrombocytopenic patients in the cardiac care unit: preliminary results of the CATCH registry. [abstract] J Am Coll Cardiol. 2004;1123–1180[501A]
  42. Rodgers JE, Anstrom KJ, Honeycutt EF, et al. Withholding direct thrombin inhibitor therapy while awaiting laboratory confirmation of heparin-induced thrombocytopenia is associated with an increased rate of thromboembolic complications: results of the CATCH registry. [Abstract] Circulation. 2004;110(Suppl):1768
  43. OASIS-2 Investigators . Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. (OASIS-2) investigators. Lancet. 1999;353:429–438
  44. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764–775
  45. Lewis B, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177–184
  46. Cochran K, Demartini TJ, Lewis BE, et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J Invasive Cardiol. 2003;15:617–621
  47. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol. 2000;12(Suppl):14F–19F
  48. Francis JL, Palmer GP, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003;75:17–22
  49. Merry AF. Bivalirudin, blood loss and graft patency in coronary artery bypass surgery. Semin Thromb Hemost. 2004;30:337–346
  50. Warkentin TE. Heparin-induced Thrombocytopenia: Diagnosis and management. Circulation. 2004;110:e454–e458
  51. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced Thrombocytopenia. Recommendations of the College of American Pathologist. Arch Pathol Lab Med. 2002;126:1415–1423

PII: S0002-8703(05)00939-7

doi: 10.1016/j.ahj.2005.10.005

American Heart Journal
Volume 152, Issue 1 , Pages 19-26 , July 2006

Article Tools

* Image Usage & Resolution